NIAID Now

76 Results

NIAID and Cuban Scientists Gather to Discuss Global Health Challenges

Recent disease outbreaks in the Americas led U.S. and Cuban scientists to hold a meeting Feb. 14-16 on Addressing Global Health Challenges Through Scientific Innovation and Biomedical Research.

Novel CMV Vaccine Generates Stronger Response in Key Immune Cells Than Previous Candidate

A messenger RNA (mRNA) vaccine designed to prevent human cytomegalovirus (CMV) elicited long-lasting CMV-specific responses from several types of immune cells, outperforming a previous vaccine concept in multiple measures in a NIAID-supported laboratory study. The findings were published in the Journal of Infectious Diseases.

Working Together to End HIV in Black Communities

Health inequities and disparities disproportionately affect Black people and other historically marginalized groups at above average rates. NIAID highlights ongoing efforts to reduce the burden of HIV among Black Americans while increasing the representation of Black communities and researchers in HIV science.

New Model for Norovirus Offers Promising Path Towards Countermeasure Development

Norovirus, a highly infectious virus that is the leading cause of diarrhea and vomiting in the U.S., has no approved therapeutics or vaccines to prevent its miserable effects. This is partly due to a lack of reliable animal models to study norovirus infection and predict how effective interventions would be in people.

World Neglected Tropical Diseases Day – Focus on Leishmaniasis

World Neglected Tropical Diseases (NTD) Day offers an opportunity to reflect on recent strides in tropical disease research and the work that remains. NIAID conducts and supports work on a wide variety of diseases—some of which rarely make headlines but cause immense suffering. An example of this is leishmaniasis, a parasitic disease that sickens hundreds of thousands of people each year, mostly in equatorial regions of the globe. In recent years, NIAID has made significant efforts to study the parasite that causes the disease and find new ways to battle it.

In People with Stable Lupus, Tapering Immunosuppressant Linked to Low Flare Risk

In people with a form of lupus called systemic lupus erythematosus (SLE), the risk for a severe flare-up of disease was low for both individuals who tapered off long-term immunosuppressive therapy and those who remained on it, a clinical trial has found. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and funded the trial. The findings were reported today in the journal The Lancet Rheumatology.

Scientists Identify Interferon-gamma as Potential SARS-CoV-2 Antiviral

Conditioning the lungs with interferon-gamma, a natural immune system protein best known for fighting bacterial infections, appears to be a strong antiviral for SARS-CoV-2, which causes COVID-19

Antibodies Passed through Placenta May Improve Survival for Infants with HIV

Certain antibodies that pass through the placenta are associated with the improved survival of infants who acquire HIV through nursing. A Kenya-based study observed that preexisting antibodies that target a region of a protein on HIV's surface were correlated with delayed HIV acquisition in infants exposed to the virus as well as a lower amount of virus circulating in the blood of infants who acquired HIV.

NIAID Team Explores Metabolism in Determining Infection Severity

The route a pathogen takes in causing infection can determine the severity of disease. NIAID scientists are looking at metabolism to determine how and why there is a difference.

Nobel Prize Awarded for Research Leading to mRNA COVID-19 Vaccines

Earlier this month, the Nobel Prize for Physiology or Medicine was awarded to Drew Weissman, M.D., Ph.D., and Katalin Karikó, Ph.D., for their groundbreaking, decades-long work on messenger RNA (mRNA) that enabled the unprecedented rapid development of the mRNA vaccines that stemmed the COVID-19 pandemic. Both Nobel laureates have connections to the National Institute of Allergy and Infectious Diseases (NIAID) and the NIH.

NIAID Workshop Examines Connection between Maternal, Fetal Immune Systems and Improving Reproductive Health

In July, NIAID hosted a workshop of technology developers, immunologists, maternal health researchers and clinicians to explore the importance and challenges of measuring, predicting and improving reproductive health in the context of maternal and fetal immune systems.

Leishmania Parasite Uses Host Antibodies in Insect Vector’s Blood Meal to Breed

It’s a finding perfect for spooky season—inside a bloodsucking insect, a parasite uses the blood of mammals to get more fit to infect unsuspecting people. In this case, the story is more troubling because it’s a real threat. The parasite is Leishmania, which causes leishmaniasis, a primarily tropical and subtropical disease that can cause skin lesions and organ damage, and can be fatal.

Scientists Discuss Prototype Pathogens for Pandemic Preparedness

A special Oct. 19 supplement to the Journal of Infectious Diseases contains nine articles intended as a summary of a National Institute of Allergy and Infectious Diseases (NIAID)-hosted pandemic preparedness workshop that featured scientific experts on viral families of pandemic concern.

SARS-CoV-2 in Airway Can Trigger Lung Fibrosis; Potential Treatment Identified

NIAID scientists and colleagues have identified a cause of COVID-induced lung fibrosis, a severe and often fatal result of COVID-19 that leaves lungs scarred, clotted and leathery, and patients struggling to breathe.

The STOMP trial evaluates an antiviral for mpox

NIAID launched the STOMP trial to determine whether the antiviral drug tecovirimat can safely and effectively treat mpox. Watch Dr. Cyrus Javan of NIAID's Division of AIDS explain the importance of the STOMP trial.

Building a Better Malaria Vaccine—NIAID Researchers Design a Paradigm-Busting Candidate

NIAID researchers used structural information about two malaria parasite proteins along with mechanistic information about the interaction between them to design and build an entirely novel candidate vaccine. When tested in rats, their “structure-based design 1” (SBD1) immunogen vaccine performed better than other experimental malaria vaccines. It also upends the conventional wisdom that successful vaccines must elicit receptor-blocking antibodies.

NIAID Researchers Study Causes of Brain Swelling in Cerebral Malaria

In children with cerebral malaria, brain swelling can cause seizures, coma, and death. Researchers from NIAID and their colleagues studied children with cerebral malaria in Malawi to better understand the underlying causes of these devastating symptoms.

HPAI Influenza Devastating Birds, Marine Mammals in Peru--Study Identifies Concerning Viral Mutations

NIAID-funded researchers working in Peru have signaled concern about the deaths of birds and marine mammals from highly pathogenic avian influenza (HPAI) that has been spreading globally.

Promising Experimental Vaccine for Tick-borne Kyasanur Forest Disease Virus

With ticks expanding their territories in many parts of the world, a NIAID research group has likewise expanded its promising vaccine research to two typically rare pathogens with potential for public health importance -- Kyasanur Forest disease and Alkhurma hemorrhagic fever.

NIAID-Supported Research is Advancing the Response to Surging Syphilis Rates

Syphilis, a common sexually transmitted infection (STI) caused by the bacteria Treponema pallidum, can result in adult neurological and organ damage, as well as congenital abnormalities, stillbirths, and neonatal deaths. More research is urgently needed to diversify the diagnostic, preventive, and therapeutic options available to alter the course of the public health threat of syphilis. NIAID supports research to address these areas including studies featured at the recent STI & HIV World Congress in Chicago.

Ohio State Scientists Evaluate Role of Deer in SARS-CoV-2 Transmission

SARS-CoV-2 evolves three times faster in white-tailed deer than in people, making NIAID-funded scientists at The Ohio State University and colleagues ask whether deer are an important reservoir for emerging virus variants.

NIAID-Funded Study Traces Evolution of Malaria Drug Resistance in E. Africa

A new NIAID-funded study shows how inconsistent malaria control measures in East Africa could be aiding the emergence of drug-resistant mutations in the primary parasite that causes malaria.

World Photo Day 2023 – Creating Colorized Microscopy Images

On this World Photo Day, we explore colorized microscopy images with NIAID microscopist John Bernbaum and visual specialist Julie Marquardt.

World Mosquito Day 2023—How Mathematical Modeling Reveals the Link Between Climate Change and Mosquito-Borne Diseases

As global temperatures rise, it has become more urgent to understand the interactions between climate, mosquitoes, and the pathogens mosquitoes transmit to humans. NIAID Now spoke to Luis Chaves, Ph.D., a 2023 Scholar with the National Institutes of Health (NIH) Climate Change and Health Initiative, about his work about the impacts of environmental change on the ecology of insect vectors and the diseases they transmit.

Relation of Parasitic Worm Infection and SARS-CoV-2 Explored

NIAID researchers used mice to investigate a possible relationship between parasitic worm infection and resistance to severe COVID-19.

Contact

Contact the NIAID Media Team.
301-402-1663

niaidnews@niaid.nih.gov